Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia
Author:
Affiliation:
1. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas
2. Haematology Department; Peter MacCallum Cancer Centre; Melbourne Victoria Australia
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28318/fullpdf
Reference26 articles.
1. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia;Keating;J Clin Oncol.,2005
2. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet.,2010
3. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia;Tam;Blood.,2008
4. Update on therapy of chronic lymphocytic leukemia;Gribben;J Clin Oncol.,2011
5. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial;Bottcher;J Clin Oncol.,2012
Cited by 55 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Miscellaneous Complications of Chimeric Antigen Receptor T-Cell Therapy;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024
2. Incorporating Immunotherapy with Radiotherapy for Lymphomas;Lymphatics;2023-12-07
3. Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapy;Clinical and Experimental Medicine;2023-10-31
4. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells;Cell Reports Medicine;2023-08
5. Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and Beyond;Cancers;2023-05-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3